SK Materials has invested $17 million in Group14 Technologies, a US-based startup developing advanced materials that can enhance the energy density of lithium-ion batteries by 50 percent.
The investments will allow Group14 Technologies to ramp up its pilot production facility and help with next year's groundbreaking of a large-scale plant in Washington next year.
SK Materials made the investments together with US-based venture capital firm OVP Venture Partners.
According to SK Materials CEO Lee Young-wook, Group14‘s innovative battery material chemistry called SCC55 maximizes high-quality production. SCC55 can replace conventional graphite materials inside anodes-- one of the four key materials inside lithium-ion batteries.
Group14 Technologies claims that SCC55 can increase a battery’s energy density by 50 percent. The manufacturing process is also much simpler.
Currently, Korean battery makers use graphite mixed with 5 percent silicon for anodes.


REPAY Stock Rises After Visa Platform Connect Collaboration
Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut
Alphabet Eyes First Australian Dollar Bond as AI Spending Drives Funding Push
Google to Buy Spirit Airlines Business Data for $10 Million to Train AI
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth
Hermès Stock Downgraded by RBC as Luxury Growth Premium Narrows
OpenAI Tightens AI Safety Monitoring After Security Incidents
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead
BofA Sees Micron EPS Topping $230 by 2030, Backs Major Stock Upside
SK Hynix Shares Surge on Record $28.6 Billion Buyback
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme
Anthropic Revenue Run Rate Hits $65 Billion as IPO Plans Accelerate
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback 



